Sanofi (NASDAQ: SNY) reported that its investigational drug efdoralprin alfa demonstrated superiority over standard-of-care therapy in treating alpha-1 antitrypsin deficiency ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE